Audit 32970

FY End
2022-09-30
Total Expended
$242.67M
Findings
2
Programs
47
Year: 2022 Accepted: 2023-06-28
Auditor: Kpmg LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

ID Ref Severity Repeat Requirement
30327 2022-001 Significant Deficiency - L
606769 2022-001 Significant Deficiency - L

Programs

ALN Program Spent Major Findings
93.498 Provider Relief Fund and American Rescue Plan (arp) Rural Distribution $22.52M Yes 1
21.027 Coronavirus State and Local Fiscal Recovery Funds $5.91M Yes 0
93.879 Medical Library Assistance $322,134 Yes 0
81.086 Conservation Research and Development $306,343 Yes 0
93.310 Trans-Nih Research Support $277,556 Yes 0
93.865 Child Health and Human Development Extramural Research $189,995 Yes 0
93.262 Occupational Safety and Health Program $177,233 Yes 0
93.867 Vision Research $173,891 Yes 0
93.397 Cancer Centers Support Grants $167,507 Yes 0
47.070 Computer and Information Science and Engineering $146,328 Yes 0
93.242 Mental Health Research Grants $109,743 Yes 0
93.838 Lung Diseases Research $104,358 Yes 0
93.353 21st Century Cures Act - Beau Biden Cancer Moonshot $102,186 Yes 0
93.121 Oral Diseases and Disorders Research $95,360 Yes 0
64.054 Research & Development $84,962 Yes 0
99.RD Contract $81,003 Yes 0
47.049 Mathematical and Physical Sciences $74,878 Yes 0
93.396 Cancer Biology Research $62,484 Yes 0
93.226 Research on Healthcare Costs, Quality and Outcomes $53,810 Yes 0
12.420 Military Medical Research and Development $48,374 Yes 0
93.399 Cancer Control $48,142 Yes 0
93.855 Allergy, Immunology and Transplantation Research $47,013 Yes 0
93.213 Research and Training in Complementary and Alternative Medicine $40,095 Yes 0
93.989 International Research and Research Training $36,895 Yes 0
93.361 Nursing Research $32,135 Yes 0
47.041 Engineering Grants $31,376 Yes 0
93.859 Biomedical Research and Research Training $27,240 Yes 0
93.393 Cancer Cause and Prevention Research $27,215 Yes 0
93.847 Diabetes, Endocrinology and Metabolism Research $25,596 Yes 0
93.279 Drug Abuse and Addiction Research Programs $18,129 Yes 0
93.846 Arthritis, Musculoskeletal and Skin Diseases Research $17,033 Yes 0
93.172 Human Genome Research $16,192 Yes 0
93.866 Aging Research $15,617 Yes 0
81.049 Office of Science Financial Assistance Program $13,064 Yes 0
93.837 Heart and Vascular Diseases Research $12,801 Yes 0
93.286 Discovery and Applied Res for Tech Innovations $10,749 Yes 0
12.910 Research and Technology Development $10,155 Yes 0
93.395 Cancer Treatment Research $9,862 Yes 0
93.398 Cancer Research Manpower $4,173 Yes 0
12.300 Basic and Applied Scientific Research Dept of Defense $3,231 Yes 0
93.110 Maternal and Child Health Federal Consolidated Programs $1,116 Yes 0
93.839 Blood Diseases and Resources Research $591 Yes 0
93.389 National Center for Research Resources $584 Yes 0
93.350 National Center for Advancing Translational Sciences $-138 Yes 0
93.853 Extramural Res Prgms in Neurosciences and Neurological Disease $-625 Yes 0
93.394 Cancer Detection and Diagnosis Research $-661 Yes 0
93.135 Cntrs for Res and Demonstration for Hlth Promotino and Dis Prev $-670 Yes 0

Contacts

Name Title Type
DPMGH9MG1X67 Amit Shrestha Auditee
8572821753 Sheila A. Harrington Auditor
No contacts on file

Notes to SEFA

Accounting Policies: (1)Definition of Reporting EntityThe accompanying Supplementary Schedule of Expenditures of Federal Awards (Schedule) presents the activity of all federal awards of Dana Farber Cancer Institute, Inc. and Subsidiaries (the Institute). All federal awards received directly from federal agencies, as well as federal awards passed through to the Institute from other agencies, are included on the Schedule. The Schedule also denotes Assistance Listing Numbers for each award and awards passed through from the Institute to other nonfederal subrecipient organizations. (2)Basis of Presentation The accounting and reporting policies of the Institute are set forth below: Basis of Presentation The Schedule is prepared on the accrual basis of accounting. Since the Schedule presents only a selected portion of the operations of the Institute, it is not intended to, and does not present the consolidated financial position or changes in net assets of the Institute. (3)Indirect Costs Indirect costs are charged to federal grants and contracts at federally approved predetermined rates. The predetermined rate for the year ended September 30, 2022 was 78%. Indirect costs recovered are included in reported federal expenditures. The Institute has elected to not use the 10% de minimis indirect cost rate allowed under the Uniform Guidance. De Minimis Rate Used: N Rate Explanation: The auditee did not use the de minimis cost rate. Indirect costs are charged to federal grants and contracts at federally approved predetermined rates. The predetermined rate for the year ended September 30, 2022 was 78%.

Finding Details

2022-001: Accuracy of PRF Reporting Grantor: Department of Health and Human Services Program Name: Provider Relief Fund Federal Award Year: October 1, 2021 through September 30, 2022 Federal Award Number: Not available Assistance Listing Number: 93.498 Criteria or Requirement PRF recipients that received one or more payments exceeding $10,000 in the aggregate during a Payment Received Period are required to report on several required data elements as part of the post-payment reporting process. Reporting must be completed and submitted to HRSA by the reporting dates specified by HRSA. Additionally, Title 45 U.S. Code of Federal Regulations Part 75 (45 CFR 75), Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards, section Title 45 U.S. Code of Federal Regulations Part 75 (45 CFR 75), Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards, section 03(a) states the non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in ?Standards for Internal Control in the Federal Government? issued by the Comptroller General of the United States or the ?Internal Control Integrated Framework?, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Condition Found, Including Perspective The dollar amount of expenses reported by management in the Health Resources and Services Administration (HRSA) portal Period 2 submission ($5,947,568) was incorrect. Management entered the total dollar amounts of expenses for Periods 1 and 2 rather than just the Period 2 expenses that should have been reported in the Period 2 submission. Period 2 expenses should have been $884,911. Possible Cause The condition found results from a misinterpretation of the PRF Reporting Period 2 submission. In completing the PRF Reporting Period 2, the HRSA website automatically populated certain PRF Reporting Period 1 data into the HRSA Reporting Period 2 portal. Management interpreted this to mean that unreimbursed COVID expenses are to be reported on a cumulative basis in the PRF Reporting Period 2 and therefore overstated unreimbursed expenses for Period 1. Effect Failure to ensure accuracy of amounts reported in the portal may result in HRSA relying on incomplete or inaccurate information associated to the Institute?s utilization of PRF funds. Questioned Costs None Statistical Validity The sample was not intended to be, and was not, a statistically valid sample. Repeat Finding from the Prior Year No. Recommendation We recommend the Institute enhance its internal controls over PRF reporting to ensure each of the data elements reported to HRSA are accurate and result in amounts consistent with its underlying records. Views of Responsible Officials There was an error in PRF Reporting Period 2 due to a misinterpretation of the instructions, which resulted in the double counting of Period 1 expenses. When it was determined there was an error, the Institute immediately contacted HRSA to request re-opening of the Period 2 report to revise the reported expenses. HRSA did not allow for the re-opening of the reporting period and maintained that the adjustment should be submitted during the Institute?s next reporting period. The Institute will make the adjustment in its next reporting period, Period 5, due by September 2023. The adjustment will net down Period 1 expenses and remedy the double counting issue. As the correct interpretation of the instructions is now known to the Institute, the expenses will be reported to HRSA accurately and consistent with the Institute records moving forward.
2022-001: Accuracy of PRF Reporting Grantor: Department of Health and Human Services Program Name: Provider Relief Fund Federal Award Year: October 1, 2021 through September 30, 2022 Federal Award Number: Not available Assistance Listing Number: 93.498 Criteria or Requirement PRF recipients that received one or more payments exceeding $10,000 in the aggregate during a Payment Received Period are required to report on several required data elements as part of the post-payment reporting process. Reporting must be completed and submitted to HRSA by the reporting dates specified by HRSA. Additionally, Title 45 U.S. Code of Federal Regulations Part 75 (45 CFR 75), Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards, section Title 45 U.S. Code of Federal Regulations Part 75 (45 CFR 75), Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards, section 03(a) states the non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in ?Standards for Internal Control in the Federal Government? issued by the Comptroller General of the United States or the ?Internal Control Integrated Framework?, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Condition Found, Including Perspective The dollar amount of expenses reported by management in the Health Resources and Services Administration (HRSA) portal Period 2 submission ($5,947,568) was incorrect. Management entered the total dollar amounts of expenses for Periods 1 and 2 rather than just the Period 2 expenses that should have been reported in the Period 2 submission. Period 2 expenses should have been $884,911. Possible Cause The condition found results from a misinterpretation of the PRF Reporting Period 2 submission. In completing the PRF Reporting Period 2, the HRSA website automatically populated certain PRF Reporting Period 1 data into the HRSA Reporting Period 2 portal. Management interpreted this to mean that unreimbursed COVID expenses are to be reported on a cumulative basis in the PRF Reporting Period 2 and therefore overstated unreimbursed expenses for Period 1. Effect Failure to ensure accuracy of amounts reported in the portal may result in HRSA relying on incomplete or inaccurate information associated to the Institute?s utilization of PRF funds. Questioned Costs None Statistical Validity The sample was not intended to be, and was not, a statistically valid sample. Repeat Finding from the Prior Year No. Recommendation We recommend the Institute enhance its internal controls over PRF reporting to ensure each of the data elements reported to HRSA are accurate and result in amounts consistent with its underlying records. Views of Responsible Officials There was an error in PRF Reporting Period 2 due to a misinterpretation of the instructions, which resulted in the double counting of Period 1 expenses. When it was determined there was an error, the Institute immediately contacted HRSA to request re-opening of the Period 2 report to revise the reported expenses. HRSA did not allow for the re-opening of the reporting period and maintained that the adjustment should be submitted during the Institute?s next reporting period. The Institute will make the adjustment in its next reporting period, Period 5, due by September 2023. The adjustment will net down Period 1 expenses and remedy the double counting issue. As the correct interpretation of the instructions is now known to the Institute, the expenses will be reported to HRSA accurately and consistent with the Institute records moving forward.